Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Young men at highest risk of schizophrenia linked with cannabis use disorder

Written by | 8 May 2023

Young men with cannabis (marijuana) use disorder have an increased risk of developing schizophrenia, according to a study led by researchers at the Mental Health Services in the… read more.

Severe mental illness linked to low attendance at cancer screening

Written by | 5 May 2023

People with severe mental illness are less likely to attend cancer screening compared to those who do not have such conditions, according to new research from the University… read more.

Supplemental New Drug Application submitted to FDA for Vraylar for the adjunctive treatment of major depressive disorder – AbbVie

Written by | 10 Apr 2022

AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in… read more.

Ketamine is effective for severe suicidal ideation

Written by | 16 Feb 2022

Ketamine is effective for the acute treatment of severe suicidal ideation, researchers reported on February 2, 2022 in The BMJ/British Medical Journal. “This study confirmed in a large… read more.

Identifying rare disease-associated genetic variants in patients with severe schizophrenia

Written by | 28 Dec 2021

New research published in the Proceedings of the National Academy of Sciences shows that examining genetic mutations in individuals with severe schizophrenia can improve the ability to detect disease-associated rare… read more.

FDA approves Invega Hayfera (6-month paliperidone palmitate), first and only twice-yearly treatment for adults with schizophrenia – Janssen Pharmaceuticals

Written by | 24 Sep 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the… read more.

FDA approves Lybalvi for schizophrenia and bipolar I disorder – Alkermes

Written by | 2 Jun 2021

Alkermes announced that the FDA has approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder,… read more.

Partners of people with schizophrenia often have a psychiatric disorder

Written by | 13 May 2021

Article written by Gary Finnegan. It is well-established that the children of people with serious mental health issues can be affected by their parents’ illness. Now new research… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.